Autopsy report · NCT02393378
Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate
Cause of deathFunding or business
“Strategic decision - to understand data from psoriasis study - NCT02129777 and wait for results of formal proof of concept study - NCT02379091.”
Life of this trial
- Ran for about 1 year 7 months before it stopped.
- 7 participants enrolled.
- Results were posted on the registry 2 years 3 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Takeda
- Sponsor type
- Industry
- Conditions
- Rheumatoid Arthritis
- Interventions
- Namilumab; Adalimumab; Methotrexate; Folic Acid
- Participants
- 7
- Sites
- 13
- Countries
- Czechia, Estonia, Russia, Spain, United Kingdom
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.